Page 1258 - Small Animal Internal Medicine, 6th Edition

1230 PART XI Immune-Mediated Disorders

Scott-Moncrieff JC, et al. Human intravenous immunoglobulin Wang A, et al. Treatment of canine idiopathic immune-mediated
therapy. Semin Vet Med Surg (Small Anim). 1997;12:178. haemolytic anaemia with mycophenolate mofetil and glucocorti-
VetBooks.ir Slovak J. Safety of oral and intravenous mycophenolate mofetil in Whelan MF, et al. Use of human immunoglobulin in addition to
coids: 30 cases (2007 to 2011). J Small Anim Pract. 2013;54(8):399.
Singer LM, et al. Leflunomide pharmacokinetics after single oral
administration to dogs. Vet Pharmacol Ther. 2011;34:609.
glucocorticoids for the initial treatment of dogs with immune-
healthy cats. J Feline Med Surg. 2017;20(2):184–188. mediated hemolytic anemia. J Vet Emerg Crit Care. 2009;19:158.
Spurlock NK, et al. A review of current indications, adverse effects, Whitley NT, et al. Immunomodulatory drugs and their application
and administration recommendations for intravenous immuno- to the management of canine immune-mediated disease. J Small
globulin. J Vet Emerg Crit Care. 2011;21:471. Anim Pract. 2011;52:70.
Steffan J, et al. Clinical trial evaluating the efficacy and safety of Woolcock AD, et al. Treatment of canine meningoencephalomy-
cyclosporine in dogs with atopic dermatitis. J Am Vet Med Assoc. elitis of unknown aetiology with mycophenolate mofetil and
2005;226:1855. corticosteroids: 25 cases (2007-2012). Vet Med Sci. 2016;2(2):125.
Tsuchiya R, et al. Prothrombotic and inflammatory effects of intra-
venous administration of human immunoglobulin G in dogs. J
Vet Intern Med. 2009;23:1164.